Terremoto Biosciences

Terremoto Biosciences, founded in 2021 and based in San Diego, is a well-funded private biotech leveraging a proprietary covalent chemistry platform to develop novel small-molecule drugs. The company has a strong leadership team with deep experience in covalent drug discovery, notably from Principia Biotech, and has raised significant capital from top-tier investors like OrbiMed and Third Rock Ventures. Its initial focus is on a precision oncology program targeting AKT1 mutations, with the broader platform enabling pursuit of both best-in-class and first-in-class medicines against challenging targets.

Proprietary covalent chemistry platform focused on selectively targeting lysine residues to create irreversible small-molecule inhibitors, enabling drug discovery against historically 'undruggable' targets.

Terremoto competes in the evolving field of targeted covalent inhibitors, facing competition from other biotechs and pharma companies advancing next-generation covalent platforms. It also competes broadly with other modalities aiming to drug 'undruggable' targets, particularly targeted protein degradation (TPD) companies. Its key differentiation is its specific focus on lysine and the proven track record of its founding team in covalent drug discovery.